drugset / Trial / NCT07367971

Drug-Drug Interaction Study of ABP-671 in Gout Patients

NCT07367971

Phase 1 Recruiting 20 enrolled Atom Therapeutics Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Timeline

Start
2026-01-23
Primary completion
2026-07-31
Completion
2026-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ABP-671 Unknown
Subject Allopurinol Small molecule

Indications